TC
HUMA icon

Trilogy Capital’s Humacyte HUMA Stock Holding History

Trilogy Capital’s Portfolio HUMA Stock Details HUMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.3K Sell
17,050
-20,750
-55% -$19.2K ﹤0.01% 403
2026
Q1 		$22.9K Sell
37,800
-17,000
-31% -$17.7K ﹤0.01% 389
2025
Q4 		$52.6K Sell
54,800
-75,000
-58% -$106K ﹤0.01% 382
2025
Q3 		$226K Hold
129,800
– – 0.01% 360
2025
Q2 		$271K Sell
129,800
-40,000
-24% -$76.8K 0.01% 305
2025
Q1 		$290K Buy
169,800
+86,300
+103% +$324K 0.02% 286
2024
Q4 		$422K Buy
+83,500
New +$413K 0.02% 244

Other funds holding HUMA

AP
Antipodes Partners Royal Exchange, Australia $5.46B AUM 26.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Trilogy Capital's HUMA Position: Q2 2026 in Review

Trilogy Capital reduced its Humacyte (HUMA) stake by 55% in Q2 2026, selling an estimated $19.2K and leaving 17,050 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #403.

Trilogy Capital first reported a position in HUMA in Q4 2024 and has held it in 7 quarters since. The position peaked at $422K in Q4 2024. 163 funds tracked by Wall St. Rank hold HUMA as of Q2 2026.

  • Trilogy Capital held 17,050 shares of Humacyte worth $13.3K as of Q2 2026.
  • Trilogy Capital sold 20,750 Humacyte shares in Q2 2026, an estimated $19.2K.
  • Humacyte made up ﹤0.01% of Trilogy Capital's portfolio in Q2 2026, its #403 holding.
  • Trilogy Capital first reported a position in Humacyte in Q4 2024 and has held it in 7 quarters since.
  • Trilogy Capital's Humacyte position peaked at $422K in Q4 2024.
  • 163 funds tracked by Wall St. Rank held Humacyte as of Q2 2026.

Based on Trilogy Capital's 13F filing for Q2 2026, filed 6 Jul 2026.